A Registry-study of ELZONRIS in Participants With BPDCN

Post-Authorisation Registry of ELZONRIS (Tagraxofusp) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.

Key Inclusion Criteria:

• Diagnosed with BPDCN, confirmed by hematopathology and biomarkers (inclusive of CD123, CD4, and CD56).
• Planning to start treatment with tagraxofusp monotherapy for BPDCN at the time of, or within 6 months prior to, informed consent form (ICF) signature or has started treatment.

Key Exclusion Criteria:

• Currently (or planning to) participating in another study or registry where BPDCN treatment outcomes are reported.
• Participating in an interventional clinical trial at the time of ICF signature.
• Known allergic reactions to components of tagraxofusp.

Note: Other protocol-specified criteria apply.